Overview

DDI (Effect of Metformin and Furosemide on Rosuvastatin PK)

Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of this trial is to investigate the relative bioavailability of rosuvastatin when given alone (Reference treatment, R) compared to when given together with one of the three different doses of metformin (10 mg, Test treatment 1 (T1); 50 mg (T2); 500 mg (T3)) or one of the two doses of furosemide (1 mg (T4); 5 mg (T5)).
Phase:
Phase 1
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Furosemide
Metformin
Rosuvastatin Calcium